Application of proteome analysis to the assessment of prognosis and response prediction in clinical oncology

Current Cancer Drug Targets

Volumn 8, Issue 2, 2008, Pages 141-145

  Röcken, Christoph ^a   Ketterlinus, Ralf ^b   Ebert, Matthias P A ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BRUKER DALTONIK GMBH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biomarker; Prediction; Prognosis; Proteomics; Translational oncology

Indexed keywords

BIOLOGICAL MARKER; CAMPTOTHECIN; CETUXIMAB; CISPLATIN; GEMCITABINE; PACLITAXEL; TRICHOSTATIN A; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; EARLY DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; NASOPHARYNX CANCER; OVARY CANCER; PANCREAS CANCER; PREDICTION; PROGNOSIS; PROSTATE CANCER; PROTEOMICS; REVIEW; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOME; PROTEOMICS;

EID: 40449104732     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908783769328     Document Type: Review

References (46)

1. Lander, E. S.; Linton, L. M.; Birren, B.; Nusbaum, C. The International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860-921.
2. Venter, J. C.; Adams, M. D.; Myers, E. W.; Li, P. W. The sequence of the human genome. Science 2001, 291, 1304-1351.
3. Röcken, C.; Ebert, M. P.; Roessner, A. Proteomics in pathology, research and practice. Pathol. Res. Pract. 2004, 200, 69-82.
4. Chou, K. C. Review: Structural bioinformatics and its impact to biomedical science. Curr. Med. Chem. 2004, 11, 2105-2134.
5. Chou, K. C.; Shen, H. B. Review: Recent progresses in protein subcellular location prediction. Anal. Biochem. 2007, 370, 1-16.
6. Lubec, G.; Afjehi-Sadat, L.; Yang, Y. W.; John J. P. Searching for hypothetical proteins: theory and practice based upon original data and literature. Prog. Neurobiol. 2005, 77, 90-127.
7. Chou, K. C.; Shen H. B. Signal-CF: a subsite-coupled and window-fusing approach for predicting signal peptides. Biochem. Biophys. Res. Comm. 2007, 357, 633-640.
8. Chou, K. C. Modelling extracellular domains of GABA-A receptors: subtypes 1, 2, 3, and 5. Biochem. Biophys. Res. Comm. 2004, 316, 636-642.
9. Chou, K. C. Molecular therapeutic targets for type-2 diabetes. J. Proteome Res. 2004, 3, 1284-1288
10. Ahmed, F. E. Molecular markers that predict response to colon cancer therapy. Expert. Rev. Mol. Diagn. 2005, 5, 353-375.
11. Schmiegel, W.; Pox, C.; Adler, G.; Fleig, W, Fölsch, U. R.; Frühmorgen, P.; Graeven, U.; Hohenberger, W.; Holstege, A.; Junginger, T.; Kühlbacher, T.; Porschen, R.; Propping, P.; Riemann, J. F.; Sauer, R.; Sauerbruch, T.; Schmoll, H. J.; Zeitz, M.; Selbmann, H. K. S3-Guidelines Conference Colorectal Carcinoma. Z. Gastroenterol. 2004, 42, 1129-1177.
12. Duffy, M. J.; van, D. A.; Haglund, C.; Hansson, L.; Holinski-Feder, E.; Klapdor, R.; Lamerz, R.; Peltomaki, P.; Sturgeon, C.; Topolcan, O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer 2007, 43, 1348-1360.
13. Locker, G. Y.; Hamilton, S.; Harris, J.; Jessup, J. M.; Kemeny, N.; Macdonald, J. S.; Somerfield, M. R.; Hayes, D. F.; Bast, Jr., R. C. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24, 5313-5327.
14. Wagner, A. D.; Schneider, P. M.; Fleig, W. E. The role of chemotherapy in patients with established gastric cancer. Best. Pract. Res. Clin. Gastroenterol. 2006, 20, 789-799.
15. Olaussen, K. A.; Dunant, A.; Fouret, P.; Brambilla, E.; Andre, F.; Haddad, V.; Taranchon, E.; Filipits, M.; Pirker, R.; Popper, H. H.; Stahel, R.; Sabatier, L.; Pignon, J. P.; Tursz, T.; Le, C. T.; Soria, J.C. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355, 983-991.
16. Chan, K. C.; Lo, Y. M. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br. J. Cancer 2007, 96, 681-685.
17. Cho, W. C. Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 2007, 6, 25.
18. Ebert, M. P.; Meuer, J.; Wiemer, J. C.; Schulz, H. U.; Reymond, M. A.; Traugott, U.; Malfertheiner, P.; Röcken, C. Identification of gastric cancer patients by serum protein profiling. J. Proteome Res. 2004, 3, 1261-1266.
19. Ward, D. G.; Suggett, N.; Cheng, Y.; Wei, W.; Johnson, H.; Billingham, L. J.; Ismail, T.; Wakelam, M. J.; Johnson, P. J.; Martin, A. Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 2006, 94, 1898-1905.
20. Ebert, M. P.; Röcken, C. Molecular screening of gastric cancer by proteome analysis. Eur. J. Gastroenterol. Hepatol. 2006, 18, 847-853.
21. Ebert, M. P.; Kruger, S.; Fogeron, M. L.; Lamer, S.; Chen, J.; Pross, M.; Schulz, H. U.; Lage, H.; Heim, S.; Roessner, A.; Malfertheiner, P.; Röcken, C. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 2005, 5, 1693-1704.
22. Ebert, M. P.; Korc, M.; Malfertheiner, P.; Röcken, C. Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J. Proteome Res. 2006, 5, 19-25.
23. Ren, H.; Du, N.; Liu, G.; Hu, H. T.; Tian, W.; Deng, Z. P.; Shi, J. S. Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. World J. Gastroenterol. 2006, 12, 2789-2792.
24. Garcea, G.; Neal, C. P.; Pattenden, C. J.; Steward, W. P.; Berry, D. P. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur. J. Cancer 2005, 41, 2213-2236.
25. Anderson, C.; Nijagal, A.; Kim, J. Molecular markers for gastric adenocarcinoma: an update. Mol. Diagn. Ther. 2006, 10, 345-352.
26. Leichman, C. G. Predictive and prognostic markers in gastrointestinal cancers. Curr. Opin. Oncol. 2001, 13, 291-299.
27. Allen, W. L.; Coyle, V. M.; Johnston, P. G. Predicting the outcome of chemotherapy for colorectal cancer. Curr. Opin. Pharmacol. 2006, 6, 332-336.
28. Catalano, V.; Baldelli, A. M.; Giordani, P.; Cascinu, S. Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. Crit. Rev. Oncol. Hematol. 2001, 38, 93-104.
29. Pasche, B.; Mulcahy, M.; Benson, A. B. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best. Pract. Res. Clin. Gastroenterol. 2002, 16, 331-345.
30. Albitar, M.; Potts, S. J.; Giles, F. J.; O'Brien, S.; Keating, M.; Thomas, D.; Clarke, C.; Jilani, I.; Aguilar, C.; Estey, E.; Kantarjian, H. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer 2006, 106, 1587-1594.
31. Wardelmann, E.; Thomas, N.; Merkelbach-Bruse, S.; Pauls, K.; Speidel, N.; Buttner, R.; Bihl, H.; Leutner, C. C.; Heinicke, T.; Hohenberger, P. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005, 6, 249-251.
32. Dziadziuszko, R.; Hirsch, F. R.; Varella-Garcia, M.; Bunn, Jr., P. A. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization - why, when, and how? Clin. Cancer Res. 2006, 12, 4409s-4415s.
33. Lièvre, A.; Bachet, J. B.; Le Corre, D.; Boige, V.; Landi, B.; Emile, J. F.; Côté, J. F.; Tomasic, G.; Penna, C.; Ducreux, M.; Rougier, P.; Penault-Llorca, F.; Laurent-Puig, P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66, 3992-3995.
34. Allal, A. S.; Kahne, T.; Reverdin, A. K.; Lippert, H.; Schlegel, W.; Reymond, M. A. Radioresistance-related proteins in rectal cancer. Proteomics 2004, 4, 2261-2269.
35. Sung, F. L.; Pang, R. T.; Ma, B. B.; Lee, M. M.; Chow, S. M.; Poon, T. C.; Chan, A. T. Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma. J. Proteome. Res. 2006, 5, 3260-3267.
36. Cecconi, D.; Donadelli, M.; Scarpa, A.; Milli, A.; Palmieri, M.; Hamdan, M.; Areces, L. B.; Rappsilber, J.; Righetti, P. G. Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. J. Proteome. Res. 2005, 4, 1909-1916.
37. Le, M. K.; Lincet, H.; Deslandes, E.; Hubert-Roux, M.; Lange, C.; Poulain, L.; Gauduchon, P.; Baudin, B. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics 2006, 6, 5183-5192.
38. Stewart, J. J.; White, J. T.; Yan, X.; Collins, S.; Drescher, C. W.; Urban, N. D.; Hood, L.; Lin, B. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol. Cell Proteomics 2006, 5, 433-443.
39. Castagna, A.; Antonioli, P.; Astner, H.; Hamdan, M.; Righetti, S. C.; Perego, P.; Zunino, F.; Righetti, P. G. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004, 4, 3246-3267.
40. Lee, K. H.; Yim, E. K.; Kim, C. J.; Namkoong, S. E.; Um, S. J.; Park, J. S. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol. Oncol. 2005, 98, 45-53.
41. Hasegawa, N.; Mizutani, K.; Suzuki, T.; Deguchi, T.; Nozawa, Y. A comparative study of protein profiling by proteomic analysis in camptothecinresistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells. Urol. Int. 2006, 77, 347-354.
42. Hayashida, Y.; Honda, K.; Osaka, Y.; Hara, T.; Umaki, T.; Tsuchida, A.; Aoki, T.; Hirohashi, S.; Yamada, T. Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin. Cancer Res. 2005, 11, 8042-8047.
43. Smith, F. M.; Gallagher, W. M.; Fox, E.; Stephens, R. B.; Rexhepaj, E.; Petricoin, E. F., III.; Liotta, L.; Kennedy, M. J.; Reynolds, J. V. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann. Surg. 2007, 245, 259-266.
44. Signor, L.; Varesio, E.; Staack, R. F.; Starke, V.; Richter, W. F.; Hopfgartner, G. Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry. J. Mass Spectrom. 2007, 42, 900-909.
45. Drexler, D. M.; Garrett, T. J.; Cantone, J. L.; Diters, R. W.; Mitroka, J. G.; Prieto Conaway, M. C.; Adams, S. P.; Yost, R. A.; Sanders, M. Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues. J. Pharmacol. Toxicol. Methods 2007, 55, 279-288.
46. Hsieh, Y.; Chen, J.; Korfmacher, W. A. Mapping pharmaceuticals in tissues using MALDI imaging mass spectrometry. J. Pharmacol. Toxicol. Methods 2007, 55, 193-200.